Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: A cohort study

BMC Medicine

Volumn 4, Issue , 2006, Pages

  Hall, Per ^a   Ploner, Alexander ^a   Bjöhle, Judith ^a   Huang, Fei ^b   Lin, Chin Yo ^c   Liu, Edison T ^c   Miller, Lance D ^c   Nordgren, Hans ^d   Pawitan, Yudi ^a   Shaw, Peter ^b   Skoog, Lambert ^a   Smeds, Johanna ^a   Wedrén, Sara ^a   Öhd, John ^a   Bergh, Jonas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL STRAIN MCF 7; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN GENOME; LOW DRUG DOSE; POSTMENOPAUSE; PROGNOSIS;

EID: 33748060189     PISSN: 17417015     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-4-16     Document Type: Article

References (51)

1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators: Influence of Estrogen plus Progestin on Breast Cancer and Mammograpy in Healthy Postmenopausal Women. JAMA 2003, 289:3243-3253.
2. Beral V, Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
3. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR: Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003, 289:3254-3263.
4. Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with a hysterectomy. The Women's Health Initiative Randomised Controlled Trial. JAMA 2004, 291:1701-1712.
5. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R: Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 2003, 12(11 Pt 1):1175-1181.
6. Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G, Veronesi U: Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 2002, 9:266-271.
7. Cheek J, Lacy J, Toth-Fejel S, Morris K, Calhoun K, Pommier RF: The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 2002, 137:1015-1021.
8. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047-1059.
9. McDonnell DP, Norris JD: Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
10. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA, Dahlman-Wright K: Expression of estrogen receptor isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003, 22:7600-7606.
11. Osborne CK: Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95:353-361.
12. Dickson RB, Stancel GM: Oestrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000, 27:135-145.
13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
14. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
15. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson PH: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001, 61:5168-5178.
16. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
17. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu E, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw P, Smeds J, Skoog L, Wedren S, Bergh J: Gene expression profiling spares early breast cancer patients from adjuvant therapy - derived and validated in two population based cohorts. Breast Cancer Res 2005, 7(6):R953-R964.
18. Hedenfalk I, Ringner M, Trent JM, Borg A: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344:539-548.
19. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM: Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 2000, 60:5977-5983.
20. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insight into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574.
21. Shan L, He M, Yu M, Qiu C, Lee NH, Liu ET, Snyderwine EG: cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. Carcinogenesis 2002, 23:1561-1568.
22. Ferno M, Bendahl PO, Brisfors A, Byman K, Ekeberg M, Ferraud L, Grankvist K, Hjalmers B, Nilsson A, Sellberg G, Skoog L, Stal O, Wingmo I: Intra- and inter-laboratory reproducibility of estrogen and progesterone receptor enzyme immunoassay in breast cancer cytosol samples - a Swedish multicenter study. Swedish Society of Cancer Study Group. Acta Oncol 1997, 36:793-798.
23. Norberg T, Klaar S, Karf G, Nordgren H, Holmberg L, Bergh J: Increased p53 mutation frequency during tumor progression - results from a breast cancer cohort. Cancer Research 2001, 61:8317-8321.
24. Egyhazi S, Bjohle J, Skoog L, Huang F, Borg AL, Frostvik Stolt M, Hagerstrom T, Ringborg U, Bergh J: Markedly increased RNA yield in primary breast tumors by addition of proteinase K to the extraction procedure - proteinase K essential for the extraction procedure for microarray studies. Clin Chem 2004, 50:975-976.
25. Affymetrix: Statistical algorithms reference guide. Technical report 2001 [http://www.affymetrix.com].
26. Efron B, Tibshirani R, Storey JD, Tusher V: Empirical Bayes Analysis of a Microarray Experiment. JASA 2001, 96:1151-1160.
27. Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, Tamanoi F, Andres DA, Perou CM: RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem 2001, 276:42259-42267 [http://www4.stanford.edu/MicroArray/SMD].
28. Scafoglio C, Ambrosino C, Cicatiello L, Altucci L, Ardovino M, Bontempo P, Medici N, Molinari AM, Nebbioso A, Facchiano A, Calogero RA, Elkon R, Menini N, Ponzone R, Biglia N, Sismondi P, Bortoli MD, Weisz A: Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem 2006 in press.
29. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
30. Venables WN, Ripley BD: Modern Applied Statistics with S Fourth edition. Springer; 2002.
31. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
32. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylsilbestrol: Recommended dosages for different categories of breast cancer patients Report of the Cooperative Breast Cancer Group. JAMA 1977, 237:2079-2085.
33. Lewis JS, Cheng D, Jordan VC: Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 2004, 90(5):944-9.
34. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprevation. J Natl Cancer Inst 2005, 97:1746-59.
35. Yuen J, Persson I, Bergkvist L, Hoover R, Schairer C, Adami HO: Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect. Cancer Causes Control 1993, 4:369-74.
36. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997, 127(11):973-80.
37. Brinton LA, Hoover R, Fraumeni JF Jr: Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986, 54(5):825-32.
38. Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND: Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994, 178(2):167-70.
39. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I: Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996, 38(3):325-34.
40. Bonnier P, Bessenay F, Sasco AJ, Beedassy B, Lejeune C, Romain S, Charpin C, Piana L, Martin PM: Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998, 79(3):278-82.
41. Holli K, Isola J, Cuzick J: Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998, 16(9):3115-20.
42. O'Connor IF, Shembekar MV, Shousha S: Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 1998, 51(12):935-8.
43. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989, 130(2):221-8.
44. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN: Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999, 91(3):264-70.
45. Jernstrom H, Frenander J, Ferno M, Olsson H: Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-user among 984 breast cancer patients. Br J Cancer 1999, 80(9):1453-8.
46. Isaksson E, Wang H, Sahlin L, von Schoultz B, Masironi B, von Schoultz E, Cline JM: Expression of estrogen receptors (alpha, beta) and insulin-like growth factor-1 in breast tissue from surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen. Breast 2002, 11(4):295-300.
47. Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, Shih J, Hwu EB, Luh F, Yen Y: The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003, 63(20):6583-94.
48. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K: p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002, 9(3):216-9.
49. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C, Endogenous Hormones Breast Cancer Collaborative Group: Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003, 95:1218-1226.
50. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE: Weight gain, body mass index, hormone replacement therapy, and post-menopausalbreast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004, 13:220-4.
51. Brenner H: Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002, 360:1131-1135.